TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS
6.1. Overview
6.2. NK Cell Therapies
6.3. NK Cell Directed Antibodies
7. GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES
7.1. Overview
7.2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
7.3. Bispecific Antibodies
8. GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION
8.1. Overview
8.2. Cancer
8.3. Immunoproliferative Disorders
8.4. Acute Infectious Diseases
8.5. Gastrointestinal Diseases
8.6. Others
9. GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER
9.1. Overview
9.2. Research & Academic Institutes
9.3. Hospitals
9.4. Specialty Clinics
10. GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Natural Killer (NK) Cell Therapeutics Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Natural Killer (NK) Cell Therapeutics Market,
11.7. Key Developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2023
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Merck KGaA.
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Bristol-Myers Squibb Company.
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Glycostem.
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Sanofi.
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Cytovia Therapeutics.
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. ImmunityBio, Inc.
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Biohaven Pharmaceuticals
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Fate Therapeutics
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. EMERcell.
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Phio Pharmaceuticals.
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 11 US: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 12 US: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 13 US: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 14 US: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 15 CANADA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 16 CANADA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 17 CANADA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 18 CANADA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 4 EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 7 GERMANY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 8 GERMANY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 10 FRANCE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 11 FRANCE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 12 FRANCE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 13 ITALY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 14 ITALY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 15 ITALY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 16 ITALY: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 17 SPAIN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 18 SPAIN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 19 SPAIN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 20 SPAIN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 21 UK: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 22 UK: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 23 UK: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 24 UK: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 25 REST OF EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 26 REST OF EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 27 REST OF EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 28 REST OF EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 29 ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 30 ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 31 ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 32 ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 33 JAPAN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 34 JAPAN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 35 JAPAN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 36 JAPAN: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 37 CHINA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 38 CHINA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 39 CHINA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 40 CHINA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 41 INDIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 42 INDIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 43 INDIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 44 INDIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 45 AUSTRALIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 46 AUSTRALIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 47 AUSTRALIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 48 AUSTRALIA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 49 SOUTH KOREA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 50 SOUTH KOREA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 51 SOUTH KOREA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 52 SOUTH KOREA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 53 REST OF ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 54 REST OF ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 55 REST OF ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 56 REST OF ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 57 REST OF THE WORLD: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 58 REST OF THE WORLD: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 59 REST OF THE WORLD: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 60 REST OF THE WORLD: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 61 MIDDLE EAST: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 62 MIDDLE EAST: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 63 MIDDLE EAST: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 64 MIDDLE EAST: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 65 AFRICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 66 AFRICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 67 AFRICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 68 AFRICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 69 LATIN AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2032 (USD BILLION)
TABLE 70 LATIN AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2032 (USD BILLION)
TABLE 71 LATIN AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 72 LATIN AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET
FIGURE 4 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY THERAPEUTICS, 2023
FIGURE 5 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY APPROACHES, 2023
FIGURE 6 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY APPLICATION, 2023
FIGURE 7 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY END USER, 2023
FIGURE 8 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 NORTH AMERICA: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 EUROPE: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 ASIA-PACIFIC: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 REST OF THE WORLD: NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 13 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 MERCK KGAA: SWOT ANALYSIS
FIGURE 16 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 18 GLYCOSTEM: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 GLYCOSTEM: SWOT ANALYSIS
FIGURE 20 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 SANOFI: SWOT ANALYSIS
FIGURE 22 CYTOVIA THERAPEUTICS.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 CYTOVIA THERAPEUTICS.: SWOT ANALYSIS
FIGURE 24 IMMUNITYBIO, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 IMMUNITYBIO, INC: SWOT ANALYSIS
FIGURE 26 BIOHAVEN PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 BIOHAVEN PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 28 FATE THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 FATE THERAPEUTICS: SWOT ANALYSIS
FIGURE 30 EMERCELL: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 EMERCELL: SWOT ANALYSIS
FIGURE 32 PHIO PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 PHIO PHARMACEUTICALS: SWOT ANALYSIS
